1. Appropriate use of PCSK9 Inhibitors in India
- Author
-
S S, Iyengar, Manish, Bansal, Jps, Sawhney, Gurpreet, Wander, S N, Narasingan, K Sarat, Chandra, Prabhakar, D, Tiny, Nair, B, Krishnakumar, Nitin, Deshpande, Neil, Bardoloi, Sadananda, Shetty, Nagaraj, Desai, A K, Pancholia, and Ajay, Swamy
- Subjects
Anticholesteremic Agents ,PCSK9 Inhibitors ,India ,Cholesterol, LDL ,Enzyme Inhibitors ,Proprotein Convertase 9 - Abstract
The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle changes, statins and ezetimibe effectively lower LDL-C and consequently improve CV outcomes. However, there are situations where these drugs fall short of achieving the target or they may not be well tolerated.
- Published
- 2019